While $ONCE Spark works through those #problems, $BMRN BioMarin is preparing for commercial sales of valrox, and 
$PFE Pfizer + $SGMO Sangamo are gearing up for the fast-approaching start of phase3 trial of a gene therapy that looks #very #competitiv 
 
https://t.co/cWBOO47Xm7